• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).

作者信息

Cherny N I, Sullivan R, Dafni U, Kerst J M, Sobrero A, Zielinski C, de Vries E G E, Piccart M J

出版信息

Ann Oncol. 2017 Nov 1;28(11):2901-2905. doi: 10.1093/annonc/mdw258.

DOI:10.1093/annonc/mdw258
PMID:27604385
Abstract
摘要

相似文献

1
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).一种标准化、通用且经过验证的方法，用于对可从抗癌疗法中预期获得的临床获益程度进行分层：欧洲医学肿瘤学会临床获益程度量表（ESMO-MCBS）。
Ann Oncol. 2017 Nov 1;28(11):2901-2905. doi: 10.1093/annonc/mdw258.
2
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS).一种标准化、通用且经过验证的方法，用于对预期从抗癌治疗中获得的临床获益程度进行分层：欧洲肿瘤内科学会临床获益程度量表（ESMO-MCBS）。
Ann Oncol. 2015 Aug;26(8):1547-73. doi: 10.1093/annonc/mdv249. Epub 2015 May 30.
3
ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers.欧洲肿瘤内科学会-临床获益量表V.1.0问答
ESMO Open. 2016 Oct 18;1(5):e000100. doi: 10.1136/esmoopen-2016-000100. eCollection 2016.
4
The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna.欧洲医学肿瘤学会“临床获益程度量表”在罕见肿瘤实体中的现场测试：维也纳医科大学对其可行性的扩展分析
ESMO Open. 2017 Jul 16;2(3):e000166. doi: 10.1136/esmoopen-2017-000166. eCollection 2017.
5
ESMO-Magnitude of Clinical Benefit Scale for haematological malignancies (ESMO-MCBS:H) version 1.0.ESMO 血液系统恶性肿瘤临床获益量表（ESMO-MCBS:H）版本 1.0。
Ann Oncol. 2023 Sep;34(9):734-771. doi: 10.1016/j.annonc.2023.06.002. Epub 2023 Jun 19.
6
Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer.评估 ESMO-MCBS v1.1 版（ESMO-MCBS v1.1）在乳腺癌辅助放疗中的应用。
ESMO Open. 2023 Jun;8(3):101206. doi: 10.1016/j.esmoop.2023.101206. Epub 2023 May 24.
7
The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna.欧洲医学肿瘤学会临床获益程度量表在日常实践中的应用：维也纳医科大学的单机构真实世界经验
ESMO Open. 2016 Jul 4;1(4):e000066. doi: 10.1136/esmoopen-2016-000066. eCollection 2016.
8
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) credit.有资格获得欧洲肿瘤内科学会-临床获益幅度评分（ESMO-MCBS）积分的生存质量数据的方法学和报告标准。
Ann Oncol. 2023 Apr;34(4):431-439. doi: 10.1016/j.annonc.2022.12.004. Epub 2022 Dec 19.
9
Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring.研究设计、实施和数据分析中的偏倚会扭曲对临床获益的评估和 ESMO-MCBS 评分。
ESMO Open. 2021 Jun;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub 2021 Apr 20.
10
Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1.分析新型疗法对晚期或转移性非小细胞肺癌的临床获益：应用 ESMO 临床获益量表 v1.1。
Acta Oncol. 2021 Sep;60(9):1225-1232. doi: 10.1080/0284186X.2021.1942546. Epub 2021 Jun 29.

引用本文的文献

1
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.晚期肝细胞癌系统治疗中生活质量与生存的整合：一项网状Meta分析。
JAMA Oncol. 2025 Aug 14. doi: 10.1001/jamaoncol.2025.2470.
2
Pharmacological class effects of anticancer drugs: opportunities for decreasing healthcare spending.抗癌药物的药理学类效应：降低医疗支出的机遇
BMJ Oncol. 2024 Jan 30;3(1):e000287. doi: 10.1136/bmjonc-2023-000287. eCollection 2024.
3
The Financial Toxicity Experience of Patients with Colorectal Cancer During Chemotherapy: A Qualitative Study.
结直肠癌患者化疗期间的经济毒性体验：一项定性研究
Curr Oncol. 2024 Dec 31;32(1):23. doi: 10.3390/curroncol32010023.
4
Application of the ESMO Magnitude of Clinical Benefit Scale to assess the clinical benefit of antibody drug conjugates in solid cancer: a systematic descriptive analysis of phase III and pivotal phase II trials.应用 ESMO 临床获益量表评估抗体药物偶联物在实体瘤中的临床获益：对 III 期和关键 II 期试验的系统描述性分析。
BMJ Open. 2024 Jun 8;14(6):e077108. doi: 10.1136/bmjopen-2023-077108.
5
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors.晚期泌尿生殖系统肿瘤III期随机对照试验中健康相关生活质量报告的分析
Cancers (Basel). 2023 Dec 4;15(23):5703. doi: 10.3390/cancers15235703.
6
Defining Priorities in Value-Based Cancer Care: Insights From the Alliance for Clinical Trials in Oncology National Cooperative Group Survey.基于价值的癌症护理中的优先事项界定：肿瘤临床研究联盟全国合作组调查的见解。
JCO Oncol Pract. 2023 Oct;19(10):932-938. doi: 10.1200/OP.23.00159. Epub 2023 Aug 31.
7
Prioritization of Surgery in Cancer Patients During the COVID-19 Pandemic: Lessons From a Failed Balancing Act.2019冠状病毒病大流行期间癌症患者手术的优先排序：平衡行动失败的教训
Ann Surg Open. 2021 Dec 14;2(4):e108. doi: 10.1097/AS9.0000000000000108. eCollection 2021 Dec.
8
Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2- Advanced Breast Cancer: Findings From a Multicountry Survey.激素受体阳性/人表皮生长因子受体 2 阴性晚期乳腺癌患者的生活质量和治疗相关副作用：一项多国家调查的结果。
Oncologist. 2023 Oct 3;28(10):856-865. doi: 10.1093/oncolo/oyad207.
9
Patient-Reported Outcomes in Ovarian Cancer: Facilitating and Enhancing the Reporting of Symptoms, Adverse Events, and Subjective Benefit of Treatment in Clinical Trials and Clinical Practice.卵巢癌患者报告结局：促进和加强临床试验及临床实践中症状、不良事件和治疗主观获益的报告
Patient Relat Outcome Meas. 2023 May 8;14:111-126. doi: 10.2147/PROM.S297301. eCollection 2023.
10
To Treat or Not to Treat? Dilemmas when Deciding on Antineoplastic Treatment in Patients With Far Advanced Cancers.是否治疗？晚期癌症患者接受抗肿瘤治疗决策中的困境。
Cancer Control. 2023 Jan-Dec;30:10732748231176639. doi: 10.1177/10732748231176639.